

[LE 0414]

APRIL 2014

Sub. Code: 2002

**FELLOWSHIP IN CLINICAL DIABETOLOGY
FINAL YEAR**

(Candidates admitted 2012-2013)

PAPER II – CLINICAL AND PRACTICAL DIABETES

Q.P. Code :232002

Time : 3 hours

Maximum : 100 marks

Answer All Questions

I. Elaborate on :

(2 X 20=40)

- 1) Diabetic Peripheral Neuropathy
- 2) Diabetes & Hypertension

II. Write Short Notes on:

(10 X 6 = 60)

- 1) Insulin Pump
- 2) Diabetes in Childhood
- 3) Charcots Foot
- 4) Diabetic Ketoacidosis
- 5) Treatment of Nephropathy
- 6) Cardiovascular Involvement in Diabetes
- 7) Screening for Diabetic Retinopathy
- 8) Renal Infections in Diabetes Mellitus
- 9) Maturity onset Diabetes in young (MODY)
- 10) Continuous Glucose Monitoring System (CGMS)

[LG 0415]

APRIL 2015

Sub. Code: 2002

**FELLOWSHIP IN CLINICAL DIABETOLOGY EXAMS
FINAL YEAR
(Candidates admitted 2012-2013)
PAPER II – CLINICAL AND PRACTICAL DIABETES**

Q.P. Code : 232002

Time : Three hours

Maximum : 100 marks

I. Elaborate on :

(2 x 20=40)

1. Coronary artery disease and diabetes mellitus.
2. Classify and discuss oral anti diabetic drugs.

II. Write notes on:

(10 x 6 = 60)

1. Pancreatic diabetes
2. Glycemic index
3. Pulmonary tuberculosis and diabetes
4. Mucormycosis in diabetes
5. Gestational diabetes
6. Microalbuminuria
7. Maturity onset diabetes in young
8. Hyperosmolar non ketotic hyperglycemia
9. Renal glycosuria
10. Maculopathy

[LI 0416]

APRIL 2016

Sub. Code: 2002

**FELLOWSHIP IN CLINICAL DIABETOLOGY EXAMS
FINAL YEAR
PAPER II – CLINICAL AND PRACTICAL DIABETES**

Q.P. Code : 232002

Time : Three hours

Maximum : 100 Marks

I. Elaborate on : (2 x 20 = 40)

1. Discuss about monogenic forms of Diabetes and describe in detail about MODY.
2. Describe advantages and disadvantages for using HbA1c as diagnostic criteria.

II. Write notes on: (10 x 6 = 60)

1. SGLT2 Inhibitors.
2. Emphysematous Pyelonephritis.
3. Management of Diabetes Dyslipidaemia.
4. Berardinelli - Seip syndrome.
5. Neonatal Hyperglycemia.
6. Brown adipose tissue.
7. Dawn and Dusk Phenomenon in diabetes care.
8. 30 yrs follow up of DCCT trial.
9. Epalrestat.
10. Glucotoxicity.

[LK 0517]

MAY 2017

Sub. Code: 2002

**FELLOWSHIP IN CLINICAL DIABETOLOGY EXAMS
FINAL YEAR
PAPER II – CLINICAL AND PRACTICAL DIABETES**

Q.P. Code : 232002

Time : Three hours

Maximum : 100 Marks

I. Elaborate on: **(2 x 20 = 40)**

1. Discuss the etiopathogenesis, clinical features and treatment strategies for diabetic autonomic neuropathy.
2. Discuss about management of hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach.

II. Write notes on: **(10 x 6 = 60)**

1. Mauriac syndrome.
2. Malignant otitis externa.
3. Management of diabetes dyslipidaemia.
4. Ambulatory blood glucose monitoring.
5. Infant of diabetic mother.
6. Brown adipose tissue.
7. GDM follow up.
8. Thrifty phenotype.
9. SGLT2 Inhibitors.
10. Lipotoxicity.

[LL 1017]

OCTOBER 2017

Sub. Code: 2002

**FELLOWSHIP IN CLINICAL DIABETOLOGY EXAMS
FINAL YEAR
PAPER II – CLINICAL AND PRACTICAL DIABETES**

Q.P. Code : 232002

Time : Three hours

Maximum : 100 Marks

I. Elaborate on: **(2 x 20 = 40)**

1. Metabolic syndrome and its management.
2. Write notes on:
 - a) Screening and prevention of diabetes.
 - b) Classification of diabetes.

II. Write notes on: **(10 x 6 = 60)**

1. Mention the peculiarities of diabetes in Asian Indians.
2. What are the biomarkers for type 2 diabetes?
3. Diagnostic criteria for gestational diabetes. Add a note on complications of gestational diabetes.
4. Write a note on management of diabetic dyslipidemia.
5. List the advantages and disadvantages of using HbA1c.
6. Enlist and briefly explain the skin disorders in diabetes.
7. Write a brief note on malignant otitis externa.
8. Explain about the injectables in diabetes treatment. Compare the pros and cons of each group.
9. Write a short note on insulin analogues.
10. Which are the safe oral hypoglycaemic agents that can be used in kidney disease? Mention the dose adjustment of each drug in kidney disease.

[LM 0518]

MAY 2018

Sub. Code: 2002

**FELLOWSHIP IN CLINICAL DIABETOLOGY EXAMS
FINAL YEAR
PAPER II – CLINICAL AND PRACTICAL DIABETES**

Q.P. Code : 232002

Time : Three hours

Maximum : 100 Marks

I. Elaborate on: **(2 x 20 = 40)**

1. Pathogenesis and management of Diabetic Keto Acidosis (DKA).
2. Diabetic foot and its management.

II. Write notes on: **(10 x 6 = 60)**

1. Enlist and briefly explain the recent cardiovascular outcome trials in Diabetes.
2. Name the groups of oral hypoglycaemic agents and their combinations commonly used for diabetes management.
3. Write on the stages of diabetic retinopathy.
4. Write a note on treatment for painful diabetic neuropathy.
5. What is incretin effect? Write briefly on incretin based drugs available for management of diabetes.
6. What is Latent Autoimmune Diabetes in the Adult (LADA)? Add a note on the difference between LADA, T2DM and T1DM.
7. What is the mechanism of action of SGLT 2 inhibitors?
8. What are the methods of screening for people with high risk of diabetes?
9. Explain the Asian Indian Phenotype.
10. Write short notes on metabolic syndrome.

[LO 0519]

MAY 2019

Sub. Code: 2002

**FELLOWSHIP IN CLINICAL DIABETOLOGY EXAMS
FINAL YEAR
PAPER II – CLINICAL AND PRACTICAL DIABETES**

Q.P. Code : 232002

Time : Three hours

Maximum : 100 Marks

I. Elaborate on: **(2 x 20 = 40)**

1. Clinical manifestations & evaluation of a patient with diabetic cardiomyopathy.
2. Various infections that can occur in a diabetic patient & brief note on Emphysematous Pyelonephritis.

II. Write notes on: **(10 x 6 = 60)**

1. Clinical presentation & management of Hyper-osmolar Non-Ketotic Coma.
2. Non-Retinal ocular manifestations of diabetes.
3. What are GLP-1 analogues? What are their advantages in the management of Diabetes Mellitus?
4. What are the cutaneous markers of diabetes?
5. What is the clinical significance of DCCT & UKPDS trials?
6. What are the features of Infant of Diabetic Mother?
7. What is the clinical presentation & management in a diabetic patient with IIIrd cranial nerve palsy?
8. Discuss the management of anemia in a patient with diabetic End Stage Renal Disease.
9. What is asymptomatic bacteriuria & what is its clinical significance?
10. What is the role of inflammation in causing diabetes & discuss the role of anti-inflammatory drugs in its management.
